For many gram-positive pathogens, conjugative plasmid transfer is an important means of spreading antibiotic resistance . Therefore, the search for alternative treatments to fight and prevent infections caused by these bacteria has become of major interest. In the present study, we evaluated the protein TraM, from the conjugative plasmid pIP501, as a potential vaccine candidate. Anti-TraM antiserum mediated in vitro opsonophagocytic killing of the strain harboring the pIP501 plasmid and also proved to be cross-reactive against other clinically relevant enterococcal and staphylococcal strains. Specificity of antibodies toward TraM was confirmed by results of an opsonophagocytic inhibition assay and Western blot. In addition, conjugative transfer experiments proved that TraM is essential for the transfer of pIP501. Finally, immunization with either TraM or anti-TraM antiserum reduced significantly the colony counts in mice livers, demonstrating that TraM is a promising vaccine candidate against enterococci and other gram-positive pathogens.
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Enterococci are among the most common pathogens associated with healthcare infections [1] . These bacteria have become a serious concern because of their ability to acquire antibiotic resistance and virulence determinants [2] , demonstrating an urgent need to improve our understanding of enterococcal virulence mechanisms and the necessity to develop new alternative treatments [3, 4] . The most important mechanism for the spread of resistance and virulence factors is conjugative plasmid transfer [5] . Most gram-positive bacteria seem to conjugate through type IV secretion systems (T4SS) [6, 7] . Plasmid pIP501, which confers resistance to multiple antibiotics and was originally isolated from Streptococcus agalactiae [8] , can be transferred to a variety of gram-positive bacteria, including streptococci, lactobacilli, lactococci, Listeria species, staphylococci, and enterococci [9] . Plasmids such as pIP501 may contribute to the spread of antibiotic-resistant bacteria among humans and may represent an attractive target for the prevention of infections caused by multidrug-resistant gram-positive bacteria. In the present study, we evaluate a previously characterized component of a T4SS (ie, TraM, a VirB8-like protein) for vaccine development against infections caused by enterococci and other gram-positive pathogens.
Bacterial strains, plasmids, and antibodies are listed in Table 1 . Enterococcus faecalis strains, which were used in the construction of the pIP501 traM knockout mutant, complementation of the mutant, and conjugative transfer assays, were grown in brain-heart infusion (BHI) medium at 37°C with shaking and supplementation with antibiotics as indicated. For all other experiments, E. faecalis and Enterococcus faecium strains were grown in tryptic soy broth (TSB) or tryptic soy agar (TSA) at 37°C without agitation. Staphylococcus aureus strains were grown in TSB with shaking or TSA at 37°C. E. coli DH5α strains were grown in LB medium at 37°C with shaking.
New Zealand white rabbits were immunized with recombinant TraH, TraJ, TraK, TraM, and TraN according to standard immunization protocols (BioGenes, Berlin, Germany). Preimmune sera were used as a negative control in all assays. Prior to use, all sera were incubated at 56°C for 30 minutes to inactivate complement. Rabbit sera were dialyzed against 1 × phosphate-buffered saline (PBS), using a 3-kDa Slide-A-Lyzer dialyse cassette (ThermoFisher Scientific, Waltham, MA).
Construction of traM In-Frame Knockout Mutant
We generated a pIP501 traM in-frame deletion mutant as described elsewhere [25] . To prevent polar effects on downstream tra genes, we deleted only 98% of traM to conserve the 2 N-terminal and 4 C-terminal codons of traM. Primers and restriction sites are listed in Table 2 .
To obtain the pKA∆traM suicide vector, we generated a pUC18 plasmid with pIP501 traM upstream and downstream regions (958 bp and 1068 bp, respectively), transformed this plasmid into E. coli DH5α, and selected clones on LB agar with 100 µg/mL ampicillin. We cut the fused upstream and downstream regions of pUC18-UPS-DWS-traM with PstI/EcoRI and inserted them into PstI/EcoRI-cut pKA. The construct was transformed into E. coli EC1000, and clones were selected on BHI agar with 250 µg/mL erythromycin. In the first homologous recombination step, E. faecalis JH2-2(pIP501) cells were electroporated with the suicide vector pKA∆traM, and transformants were selected on BHI agar with 50 µg/mL fusidic acid, 20 µg/mL erythromycin, 20 µg/mL chloramphenicol, 100 µg/mL gentamycin, and 2 mg/mL X-Gal. Integration of pKA∆traM in pIP501 at homologous sites was verified by polymerase chain reaction (PCR) analysis. In the second homologous recombination step, E. faecalis JH2-2(pIP501) with integrated pKA∆traM was grown in BHI medium with 50 µg/mL fusidic acid and 20 µg/mL chloramphenicol 3 times to the stationary growth phase and finally until an OD 600 of 0.4 was reached. To obtain the traM in-frame deletion mutant, we plated dilutions on MM9YEG agar with 50 µg/mL fusidic acid, 20 µg/mL chloramphenicol, 15 mM DL-p-chlorophenylalanine, and 2 mg/mL X-Gal and checked colonies for traM knockout, by PCR analysis. The E. faecalis JH2-2(pIP501∆traM) mutant was confirmed by sequencing of the deletion borders.
Complementation of E. faecalis JH2-2(pIP501∆traM)
For complementation of the traM deletion in E. faecalis JH2-2(pIP501∆traM), we cloned wild-type traM into expression vector pEU327 [24, 25] . With primers listed in Table 2 , we amplified traM with its ribosomal binding site (RBS), using pIP501 as template. Via restriction sites XhoII and SalI, the 1032-bp RBS-traM fragment was inserted into plasmid pEU327. E. coli DH5α cells were transformed with the recombinant construct, and clones were selected on LB agar with 100 µg/mL spectinomycin. The sequence of pEU327-RBS-traM was confirmed. For complementation, E. faecalis JH2-2 pIP501ΔtraM was transformed with pEU327-RBS-traM; transformants were selected on BHI agar with 50 µg/mL fusidic acid, 20 µg/mL chloramphenicol, and 500 µg/mL spectinomycin, with confirmation by PCR analysis.
Conjugative Transfer Assays via Biparental Matings
Biparental matings were performed with E. faecalis JH2-2(pIP501), E. faecalis JH2-2(pIP501∆traM), and E. faecalis JH2-2(pIP501ΔtraM, pEU327-RBS-traM) as described for the traH knockout mutant [25] .
Overnight cultures of donor and recipient were diluted 1:10 in BHI medium with the respective antibiotics and grown until an OD 600 of 0.5. A total of 1 mL of each culture was pelleted, washed in 1 mL of BHI medium, and resuspended in 1 mL of PBS. To enumerate recipients, serial dilutions of E. faecalis OG1X were plated on BHI agar with 1.5 mg/mL streptomycin. E. faecalis JH2-2(pIP501), E. faecalis JH2-2(pIP501∆traM), or E. faecalis JH2-2(pIP501∆traM, pEU327-RBS-traM) as donors and E. faecalis OG1X as recipient were mixed in a volume ratio of 1:9 and centrifuged for 1 minute at 6000 × g. Pellets were resuspended in 30 µL of PBS, spotted onto a BHI agar plate, and incubated overnight at 37°C. To obtain transconjugants, cells were completely recovered by rinsing plates with 1 mL of PBS, followed by streaking on BHI agar with 1.5 mg/mL streptomycin and 20 µg/mL erythromycin. All matings were done in triplicate, and recipients and transconjugants were enumerated after 24 hours. Mean transfer rates (calculated as the number of transconjugants per recipient cell) and standard deviations are given.
Opsonophagocytic Assay
In vitro opsonophagocytic assays were performed as described elsewhere [26] , using baby rabbit serum as a complement source, rabbit sera raised against recombinant proteins (antiTraH, anti-TraJ, anti-TraK, anti-TraM, and anti-TraN), the target bacterial strain, and white blood cells. Sera were used at the indicated dilution in Roswell Park Memorial Institute 1640 medium with 15% fetal bovine serum (ThermoFisher Scientific). Lyophilized baby rabbit serum was resuspended in sterile medium Roswell Park Memorial Institute 1640 medium with 15% fetal bovine serum, diluted to a final concentration of 6.7%, absorbed for 60 minutes at 4°C on a rotor rack with the target bacterial strain, and sterilized by filtration before use. White blood cells were freshly prepared from human blood specimens collected from healthy adult volunteers and adjusted to a concentration of 4 × 10 7 colony-forming unit (CFUs)/mL. Bacterial strains were grown and adjusted to a final concentration of 2 × 10 7 CFUs/mL. Each experiment was performed at least twice and measured in quadruplicate samples.
Opsonophagocytic Inhibition Assay
To determine whether the opsonic killing of anti-TraM serum was inhibited by the corresponding recombinant TraM, concentrations ranging from 0.08 to 100 µg/mL of TraM were incubated for 60 minutes at 4°C with an equal volume of a serum dilution. After incubation, the opsonophagocytic assay was performed as described above, using the mixture of inhibitor/ serum instead of the serum dilution used in an opsonophagocytic assay (described above). Inhibition assays were performed at serum dilutions yielding 70%-80% of opsonic killing of the bacterial strain without addition of the inhibitor.
Preparation of Total Protein Extracts
E. faecalis JH2-2(pAMß1), E. faecalis RE25(pRE25), E. faecalis JH2-2(pIP501), and E. faecalis JH2-2 were grown in 50 mL of TSB until an OD 600nm of 0.5 and were harvested by centrifugation (at 8400 × g for 5 minutes at 4°C). Cell pellets were washed twice with 5 mL of PBS, resuspended in 1 mL of rehydration buffer (8 M urea, 2 M thiourea, 0.5% CHAPS, and 10 mM DTT; pH 8.0), and lysed in a FastPrep cell disrupter (ThermoSavant, Cedex, France) with 1 mL of glass beads 0.1 mm in diameter twice for 30 seconds. Cell debris was removed by centrifugation (at 11.000 × g for 10 minutes at 4°C), and protein extracts were stored at −20°C.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western-Blot
Proteins were separated by SDS-PAGE under denaturing conditions with NuPAGE Novex 4%-12% bis-tris gels (ThermoFisher Scientific). Gels were blotted onto polyvinylidene fluoride membranes (ThermoFisher Scientific) by use of electro transfer as described by the manufacturer (XCell II Blot Module, ThermoFisher Scientific). Membranes were blocked with 3% skimmed milk in PBS and washed 3 times with washing buffer (PBS and 0.05% Tween 20) . Incubation of the membrane with the primary antibody at a 1:200 dilution was performed in blocking buffer for 1 hour at room temperature. Excess primary antibody was washed off, using the conditions described above. Incubation with the secondary antibody, anti-rabbit goat IgG conjugated with alkaline phosphatase (Sigma-Aldrich) at a 1:1000 dilution, was performed in blocking buffer for 1 hour at room temperature. The membrane was washed 5 times, and immune detection was carried out with the AP Conjugate Substrate Kit (Bio-Rad, Mannheim, Germany) in accordance with the manufacturer's instructions. The molecular weight of the protein was determined by comparison to the SeeBlue Plus2 prestained protein standard (ThermoFisher Scientific).
Mouse Sepsis Model

Active Immunization
The model was performed as previously described [27] . Mice were injected subcutaneously with 10 μg of antigen emulsified in 100 μL of incomplete Freund's adjuvant on days 1 and 8. On days 15 and 22, mice were boosted intraperitoneally with 10 μg of antigen suspended in saline. Challenge of the vaccinated mice was performed intravenously 7 days after final boost with 2.5 × 10 8 CFUs of S. aureus MW2. Mice were euthanized 48 hours after challenge, and S. aureus colony counts in liver were determined.
Passive Immunization
Female BALB/c mice aged 6-8 weeks (Charles River Laboratories, Cologne, Germany) were passively immunized intraperitoneally with 200 μL of anti-TraM or anti-TraJ sera 24 and 48 hours, respectively, prior to bacterial challenge. AntiTraJ serum was used as a negative control. Mice were challenged intravenously via the tail vein with approximately 1 × 10 9 CFUs of E. faecalis strains JH2-2 and JH2-2(pIP501), 4 × 10 9 CFUs of E. faecium E155, and 1.7 × 10 8 CFUs of S. aureus LAC. Mice were euthanized 48 hours after challenge, and colony counts in the liver were determined.
Ethics Statement
All animal experiments were performed in compliance with the German animal protection law (TierSchG). The mice were housed and handled in accordance with good animal practice as defined by FELASA and the national animal welfare body, GV-SOLAS. The animal welfare committees of the University of Freiburg (Regierungspräsidium Freiburg Az35/9185.81/G-07/15) approved all animal experiments.
RESULTS
TraM Is an Essential Transfer Protein for pIP501-Mediated Conjugation
Conjugative transfer experiments were performed to study the role of TraM in pIP501 transfer. We tested the transfer ability of pIP501 from the donor strains E. faecalis JH2-2(pIP501), E. faecalis JH2-2(pIP501∆traM), and E. faecalis JH2-2(pIP501∆traM complemented with pEU327-RBS-traM) to the recipient E. faecalis OG1X. E. faecalis JH2-2(pIP501) and E. faecalis JH2-2(pIP501∆traM) were obtained from the same merodiploid E. faecalis JH2-2(pIP501::pKA∆traM) strain. Mean transfer rates (±SD) of this merodiploid-derived E. faecalis JH2-2(pIP501) (7.1 × 10 −6 ± 4.1 × 10 −6 transconjugants per recipient) were in the range of that for the wild-type strain (2.3 × 10 −5 ± 2.5 × 10 −7 transconjugants per recipient). No pIP501 transfer was detectable for the traM knockout mutant, E. faecalis JH2-2(pIP501∆traM), providing evidence that TraM is an essential component in the pIP501 conjugative transfer process. We complemented E. faecalis JH2-2(pIP501∆traM) in trans with pEU327-RBS-traM encoding wild-type traM. The complemented mutant, E. faecalis JH2-2(pIP501∆traM, pEU327-RBS-traM), showed full recovery of wild-type transfer capacity (mean [±SD], 1.4 × 10 −4 ± 1.6 × 10 −5 transconjugants per recipient), thus excluding polar effects of traM deletion on downstream tra genes.
TraM Induces Opsonic Antibodies
The serum raised against the recombinant TraM was evaluated against strain E. faecalis JH2-2, which lacks and harbors the pIP501 plasmid. As shown in Figure 1 , anti-TraM antibodies effectively mediated opsonophagocytic killing of E. faecalis JH2-2 containing plasmid pIP501 ( Figure 1A ) and showed no activity against the strain lacking the plasmid ( Figure 1B) . Dosedependent opsonophagocytic activity of the anti-TraM antibodies was proved by testing different concentrations of serum and titering out their activity. A maximal opsonophagocytic activity at a 1:10 dilution resulted in 80% of killing of E. faecalis JH2-2 (B) . C, Anti-TraM antibodies mediate opsonophagocytic killing of the strain harboring the pIP501 plasmid. E. faecalis JH2-2(pIP501) was also tested using anti-TraH, anti-TraJ, anti-TraK, and anti-TraN antibodies. Opsonophagocytic killing activity of anti-TraM serum at dilutions of 1:10 and 1:50 was compared to the activity exhibited by anti-TraH, anti-TraJ, anti-TraK, and anti-TraN sera at dilutions of 1:10 and 1:50. AntiTraM serum mediated opsonophagocytic killing of the target strain, while very low killing activity was observed when anti-TraH, anti-TraK, anti-TraJ, and anti-TraN sera were used. Bars represent the mean of quadruplicate measurements of each sample, and the error bars the standard error of the mean.
JH2-2(pIP501), and a reduction in killing was observed when using higher dilutions of serum.
The activity of antibodies raised against other T4SS proteins from plasmid pIP501 was also evaluated using E. faecalis JH2-2(pIP501). Only antibodies raised against TraM effectively mediated opsonophagocytic killing of the bacterial strain, exhibiting killing percentages of >40% ( Figure 1C ).
Opsonic Anti-TraM Antibodies Are Specific for TraM
To evaluate whether antibodies involved in opsonophagocytic killing of E. faecalis JH2-2(pIP501) specifically target TraM, an opsonophagocytic inhibition assay was conducted. Antibodies at a 1:10 dilution yielding an opsonic killing percentage of approximately 80% were incubated with decreasing amounts of recombinant TraM (ie, 100 µg/mL, 20 µg/mL, 4 µg/ mL, and 0.8 µg/mL) prior to the opsonophagocytic assays. Use of absorbed antibody dilutions in opsonophagocytic assays resulted in a reduction of opsonophagocytic killing activity against the targeted strain ( Figure 2A ). The activity was completely abolished in the presence of the highest concentration of protein (100 µg/mL) and was gradually recovered by diminishing the concentration of TraM. The specificity of anti-TraM antibodies was also evaluated using S. aureus MW2 ( Figure 2B ). Opsonophagocytic killing activity of anti-TraM antibodies was abolished as well by using the highest concentration of recombinant TraM, and activity was recovered by using increasing dilutions of the protein.
TraM Homologs Identified in Plasmids pRE25 and pAMß1 Are Immunoreactive With Anti-TraM Antibodies
Total protein extracts of E. faecalis JH2-2 and of the same strain harboring the plasmids pIP501, pRE25, or pAMß1 were analyzed for the ability of anti-TraM antibodies to target homologous proteins from the T4SSs of these conjugative plasmids. In Figure 2C can be observed that anti-TraM antibodies were immunoreactive not only with TraM extracted from E. faecalis JH2-2(pIP501), but also with TraM from the strain harboring pRE25 or pAMß1 encoding a putative T4SS similar to that of pIP501. No immunoreactivity was observed for the strain without these plasmids. Although the theoretical molecular weight of TraM is 37.5 kDa, we observed a band at around 40 kDa. This may be explained by the positive charge of TraM, which may yield an apparent higher molecular weight by SDS-PAGE [28] . Figure 2 . Specificity of anti-TraM serum toward TraM. A and B, Opsonophagocytic inhibition assay was performed using Enterococcus faecalis JH2-2(pIP501) (A) and the anti-TraM serum-susceptible Staphylococcus aureus strain MW2 (B). Inhibition of opsonophagocytic killing by anti-TraM antibodies was tested by preincubating 100 µg/ mL, 20 µg/mL, 4 µg/mL, and 0.8 µg/mL of TraM with anti-TraM antibodies at a 1:10 dilution for 1 hour at 4°C prior to the assay. Opsonic killing of the target strains with nonabsorbed antibodies was used to assess the reduction of opsonic killing produced by each inhibitor's concentration. C, The specificity of anti-TraM antibodies was also tested by Western blot. Anti-TraM serum was used at 1:200 dilution against 10 µg of total protein extracts from bacterial strains E. faecalis JH2-2(pAMß1) (lane 1), E. faecalis RE25(pRE25) (lane 2), E. faecalis JH2-2(pIP501) (lane 3), and E. faecalis JH2-2 (lane 4). The expected band, corresponding to the molecular weight of TraM (37.5 kDa), is indicated by the arrow to the right. Lane S corresponds to SeeBlue Plus2 Prestained Protein Standard. Statistical analysis was done by analysis of variance with the Dunnett post hoc test. Bars represent the mean of quadruplicate measurements of each sample, and the error bars represent the standard error of the mean. NS, nonsignificant. *P < .1, **P < .01, and ***P < .001.
antibodies, while S. aureus exhibited more resistance to phagocytosis mediated by these antibodies. A reduction of killing in a dose-dependent manner was observed for all tested bacterial strains by using increasing dilutions of anti-TraM serum.
Opsonic Anti-TraM Antibodies Mediate Bacterial Clearance In Vivo
To determine whether anti-TraM antibodies confer protection to mice against bacterial infection, mice were passively immunized twice within 48 hours prior to bacterial challenge. Nonopsonic serum raised against the cell-membrane-associated protein TraJ [6] was used as a negative control. Bacterial strains E. faecalis JH2-2, E. faecalis JH2-2(pIP501), E. faecium E155, and S. aureus LAC were tested in a mouse sepsis model. Bacterial counts in livers of mice passively immunized with anti-TraM serum were significantly lower in comparison to those in mice immunized with anti-TraJ antibodies (Figure 4 ). Anti-TraM serum conferred protection to mice against bacteremia caused by all the different strains tested. Animals passively immunized with anti-TraM serum showed reduction in CFUs when compared to controls (anti-TraJ serum), with values of 66% for E. faecalis JH2-2, 96% for E. faecalis JH2-2(pIP501), 86% for E. faecium E155, and 83% for S. aureus LAC. Statistical significance was highest for E. faecalis JH2-2(pIP501), E. faecium E155, and S. aureus LAC.
Active Immunization With TraM Protein Induces Protective Antibodies
In Vivo
Vaccination of mice with TraM was performed to demonstrate that the protein stimulates the immune system by inducing protective antibodies that mediate clearance of bacteria in vivo. Mice were actively immunized with 4 doses of 10 µg of protein.
Seven days after the final boost with TraM, mice were challenged with intravenous injection of S. aureus MW2. The livers of the animals showed a statistically significant reduced number of S. aureus MW2 (78% reduction of CFUs when compared to control animals; Figure 5 ).
DISCUSSION
The idea of vaccination to prevent nosocomial infections has been pursued by several groups and also by pharmaceutical companies [29, 30] . Although polysaccharide antigens have been considered as good vaccine targets, they are T-cellindependent antigens and therefore show poor immunogenicity [31] . Therefore, conjugation to a carrier protein is advantageous [32] . Several polysaccharide-based conjugate vaccines are commercially available, and all of them use a highly immunogenic protein (eg, tetanus toxoid, diphtheria toxoid, or cross-reactive material 197) [33] [34] [35] . Protein-based vaccines show good immunogenicity and have serotype-independent coverage and low production costs [36] , but proteins are often variable, and single mutations may affect cross-reactivity [37] .
S. aureus and Enterococcus species are important pathogens in the hospital, and their resistance to multiple drugs complicates therapy [33, 38] . Development of vaccines against these nosocomial pathogens seems promising, although mechanisms leading to protective immunity are only partly understood [39] . Several enterococcal antigens (polysaccharides and proteins) have been demonstrated not only to confer in vivo protection against enterococcal infections, but also to be cross-reactive to other gram-positive pathogens, such as staphylococci and streptococci [13, 14, 27, 40, 41] .
Conjugative plasmids such as pIP501 encode a complete T4SS comprising 15 putative transfer (Tra) proteins [42] . Attempts to elucidate the structure and function of T4SS proteins from gram-positive plasmids have been pursued [7, 10, 25, 42] . However, functional characterization of most of these proteins is still missing. Among the described proteins from plasmid pIP501, TraA, a relaxase protein, has been demonstrated to function as a site-specific DNA cleavage enzyme [6, [43] [44] [45] . TraE and TraJ are believed to be involved in energizing the conjugation process [5, 6] . TraJ has been demonstrated to interact with TraA, confirming its putative role as coupling protein [5] . TraJ might require the help of accessory protein TraI to be recruited to the cell membrane [46] . The peptidoglycan-cleaving TraG protein has been shown to be indispensable for pIP501 transfer in E. faecalis [23] . TraK seems to have an exclusive role in the pIP501 T4SS, owing to the very limited number of structural relatives in gram-positive systems [10] . This protein, as well as TraM, is localized in the cell wall, but surface accessibility could be only shown for TraM [42] .
Our results indicate that TraM, a VirB8-like protein with putative recruitment function in the T4S process, is surface exposed and the target of opsonic antibodies. In animal models, protection through anti-TraM antibodies was significantly higher when mice were infected with bacteria expressing TraM as compared to bacteria without T4SS. However, a baseline level of protection was also seen when mice infected with bacteria without T4SS received serum raised against TraM. This could be explained by the differences in the preexisting antibodies against other surface antigens of the E. faecalis JH2-2 strain (eg, anti-lipoteichoic acid) [47, 48] . In the E. faecalis traM deletion mutant, conjugative plasmid transfer was completely abolished, confirming that the protein is indispensable for plasmid transfer in enterococci. Casu et al used structural information of characterized VirB8 homologs to analyze interactions of these proteins with small-molecule inhibitors of Brucella VirB8 dimerization [49] . They showed that some inhibitors bind to a structurally conserved surface groove, thereby inhibiting pKM101 plasmid conjugation. An approach that targets specific T4SS proteins would not only impair multidrug-resistant bacteria but also inhibit plasmid transfer, thereby preventing spread of antibiotic resistance.
None of the conjugative transfer systems of gram-positive bacteria are well characterized [7] . Nevertheless, we found that anti-TraM antibodies were also active against community-acquired methicillin-resistant S. aureus (ie, S. aureus LAC, MW2, and SF8300) and multidrug-resistant E. faecium E155, indicating that these bacteria may possess similar T4SS proteins. Crossreactivity of anti-TraM antibodies to proteins from S. aureus and E. faecium E155 has been demonstrated ( Supplementary  Data 1) . Furthermore, TraM cross-reactivity was confirmed by Western blot against several other conjugative plasmids from E. faecalis.
In summary, TraM seems to be a promising novel vaccine candidate against enterococcal infections. This protein, as well as other surface proteins, could be used alone or conjugated to polysaccharides. Other nosocomial gram-positive bacteria, such as methicillin-resistant S. aureus, have been shown to harbor similar broad-host-range plasmids that carry antibiotic resistance and are transferred through T4SSs [50] . Their role in the spread of antibiotic resistance makes T4SSs attractive targets because these plasmids may be the Achilles' heel of multidrug-resistant bacteria.
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